|
1
|
Ghoncheh M, Pournamdar Z and Salehiniya H:
Incidence and mortality and epidemiology of breast cancer in the
world. Asian Pac J Cancer Prev. 17:43–46. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Caiazza F, McGowan PM, Mullooly M, Murray
A, Synnott N, O'Donovan N, Flanagan L, Tape CJ, Murphy G, Crown J
and Duffy MJ: Targeting ADAM-17 with an inhibitory monoclonal
antibody has antitumor effects in triple-negative breast cancer
cells. Br J Cancer. 112:1895–1903. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ocaña A, Amir E, Seruga B, Martin M and
Pandiella A: The evolving landscape of protein kinases in breast
cancer: Clinical implications. Cancer Treat Rev. 39:68–76. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Black RA, Rauch CT, Kozlosky CJ, Peschon
JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P,
Srinivasan S, et al: A metalloproteinase-disintegrin that releases
tumor-necrosis factor-alpha from cells. Nature. 385:729–733. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moss ML, Jin SL, Milla ME, Bickett DM,
Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, et
al: Cloning of a disintegrin metalloproteinase that processes
precursor tumor-necrosis factor-alpha. Nature. 385:733–736. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baumgart A, Seidl S, Vlachou P, Michel L,
Mitova N, Schatz N, Specht K, Koch I, Schuster T, Grundler R, et
al: ADAM17 regulates epidermal growth factor receptor expression
through the activation of Notch1 in non-small cell lung cancer.
Cancer Res. 70:5368–5378. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Santiago-Josefat B, Esselens C, Bech-Serra
JJ and Arribas J: Post-transcriptional up-regulation of ADAM17 upon
epidermal growth factor receptor activation and in breast tumors. J
Biol Chem. 282:8325–8331. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Murphy G: The ADAMs: Signaling scissors in
the tumor microenvironment. Nat Rev Cancer. 8:929–941. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zheng X, Jiang F, Katakowski M, Kalkanis
SN, Hong X, Zhang X, Zhang ZG, Yang H and Chopp M: Inhibition of
ADAM17 reduces hypoxia-induced brain tumor cell invasiveness.
Cancer Sci. 98:674–684. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rego SL, Helms RS and Dréau D: Tumor
necrosis factor-alpha-converting enzyme activities and
tumor-associated macrophages in breast cancer. Immunol Res.
58:87–100. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maretzky T, Zhou W, Huang XY and Blobel
CP: A transforming Src mutant increases the bioavailability of EGFR
ligands via stimulation of the cell-surface metalloproteinase
ADAM17. Oncogene. 30:611–618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qin CF, Hao K, Tian XD, Xie XH and Yang
YM: Combined effects of EGFR and Hedgehog signaling pathway
inhibition on the proliferation and apoptosis of pancreatic cancer
cells. Oncol Rep. 28:519–526. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guo G, Gong K, Wohlfeld B, Hatanpaa KJ,
Zhao D and Habib AA: Ligand-independent EGFR signaling. Cancer Res.
75:3436–3441. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
McGowan PM, Ryan BM, Hill AD, McDermott E,
O'Higgins N and Duffy MJ: ADAM-17 expression in breast cancer
correlates with variables of tumor progression. Clin Cancer Res.
13:2335–2343. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
McGowan PM, McKiernan E, Bolster F, Ryan
BM, Hill AD, McDermott EW, Evoy D, O'Higgins N, Crown J and Duffy
MJ: ADAM-17 predicts adverse outcome in patients with breast
cancer. Ann Oncol. 19:1075–1081. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kenny PA: TACE: A new target in epidermal
growth factor receptor-dependent tumors. Differentiation.
75:800–808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Meng X, Hu B, Hossain MM, Chen G, Sun Y
and Zhang X: ADAM17-siRNA inhibits MCF-7 breast cancer through
EGFR-PI3K-AKT activation. Int J Oncol. 49:682–690. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rose-John S: ADAM17, shedding, TACE as
therapeutic targets. Pharmacol Res. 71:19–22. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rao DD, Vorhies JS, Senzer N and
Nemunaitis J: siRNA vs. shRNA: Similarities and differences. Adv
Drug Deliv Rev. 61:746–759. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gvozdeva OV, Prassolov VS, Zenkova MA,
Vlassov VV and Chernolovskaya EL: Silencing of inducible
immunoproteasome subunit expression by chemically modified siRNA
and shRNA. Nucleosides Nucleotides Nucleic Acids. 35:389–403. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stewart SA, Dykxhoorn DM, Palliser D,
Mizuno H, Yu EY, An DS, Sabatini DM, Chen IS, Hahn WC, Sharp PA, et
al: Lentivirus-delivered stable gene silencing by RNAi in primary
cells. RNA. 9:493–501. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Klinghoffer RA, Magnus J, Schelter J,
Mehaffey M, Coleman C and Cleary MA: Reduced seed region-based
off-target activity with lentivirus-mediated RNAi. RNA. 16:879–884.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Y and Lazo JS: Metastasis-associated
phosphatase PRL-2 regulates tumor cell migration and invasion.
Oncogene. 31:818–827. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zheng X, Jiang F, Katakowski M, Zhang ZG,
Lu QE and Chopp M: ADAM17 promotes breast cancer cell malignant
phenotype through EGFR-PI3K-AKT activation. Cancer Biol Ther.
8:1045–1054. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gao MQ, Kim BG, Kang S, Choi YP, Yoon JH
and Cho NH: Human breast cancer-associated fibroblasts enhance
cancer cell proliferation through increased TGF-alpha cleavage by
ADAM17. Cancer Lett. 336:240–246. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yoshioka T, Hosoda M, Yamamoto M, Taguchi
K, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y and Yamashita H:
Prognostic significance of pathologic complete response and Ki67
expression after neoadjuvant chemotherapy in breast cancer. Breast
Cancer. 22:185–191. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hao S, He ZX, Yu KD, Yang WT and Shao ZM:
New insights into the prognostic value of Ki-67 labeling index in
patients with triple-negative breast cancer. Oncotarget.
7:24824–24831. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang W, Wu J, Zhang P, Fei X, Zong Y, Chen
X, Huang O, He JR, Chen W, Li Y, et al: Prognostic and predictive
value of Ki-67 in triple-negative breast cancer. Oncotarget.
7:31079–31087. 2016.PubMed/NCBI
|
|
29
|
Brand TM, Iida M, Luthar N, Starr MM,
Huppert EJ and Wheeler DL: Nuclear EGFR as a molecular target in
cancer. Radiother Oncol. 108:370–377. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tomas A, Futter CE and Eden ER: EGF
receptor trafficking: Consequences for signaling and cancer. Trends
Cell Biol. 24:26–34. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li X, Wang Q, Fu L, Liu M and Yu X:
Expression of PTEN, p53, and EGFR in the molecular subtypes of
breast carcinoma and the correlation among them. Zhong Nan Da Xue
Xue Bao Yi Xue Ban. 40:973–978. 2015.(In Chinese). PubMed/NCBI
|
|
32
|
Lluch A, Eroles P and Perez-Fidalgo JA:
Emerging EGFR antagonists for breast cancer. Expert Opin Emerg
Drugs. 19:165–181. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Howe LR and Brown PH: Targeting the
HER/EGFR/ErbB family to prevent breast cancer. Cancer Prev Res.
4:1149–1157. 2011. View Article : Google Scholar
|
|
34
|
Kim S, Lee J, Oh SJ, Nam SJ and Lee JE:
Differential effect of EGFR inhibitors on tamoxifen-resistant
breast cancer cells. Oncol Rep. 34:1613–1619. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xiao LJ, Lin P, Lin F, Liu X, Qin W, Zou
HF, Guo L, Liu W, Wang SJ and Yu XG: ADAM17 targets MMP-2 and MMP-9
via EGFR-MEK-ERK pathway activation to promote prostate cancer cell
invasion. Int J Oncol. 40:1714–1724. 2012.PubMed/NCBI
|
|
36
|
Hers I, Vincent EE and Tavare JM: Akt
signalling in health and disease. Cell Signal. 23:1515–1527. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Toker A and Marmiroli S: Signaling
specificity in the Akt pathway in biology and disease. Adv Biol
Regul. 55:28–38. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Martini M, De Santis MC, Braccini L,
Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An
updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dobashi Y, Tsubochi H, Matsubara H, Inoue
J, Inazawa J, Endo S and Ooi A: Diverse involvement of isoforms and
gene aberrations of Akt in human lung carcinomas. Cancer Sci.
106:772–781. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dobashi Y, Sato E, Oda Y, Inazawa J and
Ooi A: Significance of Akt activation and AKT gene increases in
soft tissue tumors. Hum Pathol. 45:127–136. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Won JK, Yang HW, Shin SY, Lee JH, Heo WD
and Cho KH: The crossregulation between ERK and PI3K signaling
pathways determines the tumoricidal efficacy of MEK inhibitor. J
Mol Cell Biol. 4:153–163. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Saini KS, Loi S, de Azambuja E,
Metzger-Filho O, Saini ML, Ignatiadis M, Dancey JE and
Piccart-Gebhart MJ: Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK
pathways in the treatment of breast cancer. Cancer Treat Rev.
39:935–946. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Takai M, Nakagawa T, Tanabe A, Terai Y,
Ohmichi M and Asahi M: Crosstalk between PI3K and Ras pathways via
protein phosphatase 2A in human ovarian clear cell carcinoma.
Cancer Biol Ther. 16:325–335. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Djukom C, Porro LJ, Mrazek A, Townsend CM
Jr, Hellmich MR and Chao C: Dual inhibition of PI3K and mTOR
signaling pathways decreases human pancreatic neuroendocrine tumor
metastatic progression. Pancreas. 43:88–92. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tandon M, Chen Z and Pratap J: Role of
Runx2 in crosstalk between Mek/Erk and PI3K/Akt signaling in
MCF-10A cells. J Cell Biochem. 115:2208–2217. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hoeflich KP, O'Brien C, Boyd Z, Cavet G,
Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, et
al: In vivo antitumor activity of MEK and phosphatidylinositol
3-kinase inhibitors in basal-like breast cancer models. Clin Cancer
Res. 15:4649–4664. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Xu C, Sun X, Qin S, Wang H, Zheng Z, Xu S,
Luo G, Liu P, Liu J, Du N, et al: Let-7a regulates mammosphere
formation capacity through Ras/NF-κB and Ras/MAPK/ERK pathway in
breast cancer stem cells. Cell Cycle. 14:1686–1697. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hung AC, Tsai CH, Hou MF, Chang WL, Wang
CH, Lee YC, Ko A, Hu SC, Chang FR, Hsieh PW and Yuan SS: The
synthetic β-nitrostyrene derivative CYT-Rx20 induces breast cancer
cell death and autophagy via ROS-mediated MEK/ERK pathway. Cancer
Lett. 371:251–261. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Deschenes-Simard X, Gaumont-Leclerc MF,
Bourdeau V, Lessard F, Moiseeva O, Forest V, Igelmann S, Mallette
FA, Saba-El-Leil MK, Meloche S, et al: Tumor suppressor activity of
the ERK/MAPK pathway by promoting selective protein degradation.
Genes Dev. 27:900–915. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Santarpia L, Lippman SM and El-Naggar AK:
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy.
Expert Opin Ther Targets. 16:103–119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhang XM, Li BL, Song M and Song JY:
Expression and significance of ERK protein in human breast
carcinoma. Chin J Cancer Res. 16:269–273. 2004. View Article : Google Scholar
|
|
52
|
Beck Gooz M, Maldonado EN, Dang Y, Amria
MY, Higashiyama S, Abboud HE, Lemasters JJ and Bell PD: ADAM17
promotes proliferation of collecting duct kidney epithelial cells
through ERK activation and increased glycolysis in polycystic
kidney disease. Am J Physiol Renal Physiol. 307:F551–F559. 2014.
View Article : Google Scholar : PubMed/NCBI
|
